Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.

por Gooding, R., Riches, P., Dadian, G., Moore, J., Gore, M.
Publicado 1995

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients w...

por Johnston, S. R., Constenla, D. O., Moore, J., Atkinson, H., A'Hern, R. P., Dadian, G., Riches, P. G., Gore, M. E.
Publicado 1998

Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck.

por Gore, M. E., Riches, P., MacLennan, K., O'Brien, M., Moore, J., Dadian, G., Lorentzos, A., Garth, R., Moskovic, E., Archer, D.
Publicado 1992

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.

por Ahmed, F. Y., Leonard, G. A., A'Hern, R., Taylor, A. E., Lorentzos, A., Atkinson, H., Moore, J., Nicolson, M. C., Riches, P. G., Gore, M. E.
Publicado 1996